BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:27T51 readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of 27T51\, from ClinicalTrials.gov estimates
 .
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06469281-11295@assetmemo.bio
DTSTAMP:20261121T005445Z
DTSTART;VALUE=DATE:20300527
DTEND;VALUE=DATE:20300528
SUMMARY:27T51: Phase 1 readout est. (NCT06469281)
DESCRIPTION:27T51\, phase 1\, Ovarian Cancer.\nStudy: A Study to Learn if 2
 7T51\, a Mucin-16 (MUC16) Protein Targeting Immune Cell Therapy\, Administ
 ered Alone or in Combination is Safe and How Well it Works for Adult Parti
 cipants With Recurrent or Treatment Resistant Ovarian Cancers\nEstimated p
 rimary completion: 27 May 2030. This is a ClinicalTrials.gov estimate\, no
 t a confirmed readout date\, and it can move.\nDrug page: https://assetmem
 o.bio/drug/27t51#upcoming-events\nRegistry record: https://clinicaltrials.
 gov/study/NCT06469281
URL:https://assetmemo.bio/drug/27t51#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
